Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylamine SCHEMBL7273952 | 0.98 | TAAR1 (0.56) | TAAR1SLC6A2SIGMAR1SLC6A4SLC6A3 | |
| SCHEMBL8983689 | 0.95 | TAAR1 (0.56) | TAAR1SLC6A2SIGMAR1SLC6A4SLC6A3 | |
| SCHEMBL14799062 | 0.95 | TAAR1 (0.56) | TAAR1SLC6A2SIGMAR1SLC6A4SLC6A3 | |
| SCHEMBL535702 | 0.95 | TAAR1 (0.56) | TAAR1SLC6A2SIGMAR1SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL5082413 | 0.93 | TAAR1 (0.54) | TAAR1SLC6A2SIGMAR1SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL7266799 | 0.91 | TAAR1 (0.52) | TAAR1SLC6A2SIGMAR1SLC6A4SLC6A3 | |
| SCHEMBL9069704 | 0.91 | ESR1 (0.61) | TAAR1SLC6A2SIGMAR1SLC6A4SLC6A3 | |
| Formamide SCHEMBL7267893 | 0.88 | TAAR1 (0.50) | TAAR1SLC6A2SIGMAR1SLC6A4SLC6A3 | |
| SCHEMBL25381540 | 0.85 | TAAR1 (0.52) | TAAR1SLC6A2SIGMAR1SLC6A4SLC6A3 | |
| SCHEMBL8583523 | 0.85 | TAAR1 (0.52) | TAAR1SLC6A2SIGMAR1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007017652-A2 | ARYLAKYLAMINES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| EP-0356035-B1 | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties | ASTRA AB (SE) | 1996-03-13 | — | — | EP | claimed |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-11 | — | — | US | disclosed |
| US-11213494-B2 | Compositions and methods for the treatment of pervasive development disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-10555916-B2 | NMDAR antagonist for the treatment of pervasive development disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-11 | — | — | US | disclosed |
| EP-3485882-A1 | COMPOSITIONS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | Case Western Reserve University (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-2948135-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | UNIV CASE WESTERN RESERVE (US) | 2019-01-02 | — | — | EP | disclosed |
| US-20180008559-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-01-11 | — | — | US | disclosed |
| US-20150359759-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2015-12-17 | — | — | US | disclosed |
| EP-2948135-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | Case Western Reserve University (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014117089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-07-31 | — | — | WO | disclosed |
| US-5331007-A | Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties | FISONS CORPORATION (US) | 1994-07-19 | — | — | US | disclosed |
| EP-0279937-B1 | 2-AMINOACETAMIDE DERIVATIVES | FISONS CORPORATION (US) | 1991-10-09 | — | — | EP | disclosed |
| US-5047541-A | 2-azacyclocarboxamide derivatives | FISONS CORPORATION (US) | 1991-09-10 | — | — | US | disclosed |
| WO-1991011995-A1 | ARYLALKYL-AMINES AND -AMIDES HAVING ANTICONVULSANT AND NEUROPROTECTIVE PROPERTIES | FISONS CORPORATION (US) | 1991-08-22 | — | — | WO | disclosed |
| EP-0401253-A1 | 2-AMINO ACETAMIDE DERIVATIVES | FISONS CORPORATION (US) | 1990-12-12 | — | — | EP | disclosed |
| EP-0356035-A2 | Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties | Astra Aktiebolag (SE) | 1990-02-28 | — | — | EP | disclosed |
| WO-1989006646-A1 | 2-AMINO ACETAMIDE DERIVATIVES | FISONS CORPORATION (US) | 1989-07-27 | — | — | WO | disclosed |
| EP-0279937-A1 | 2-Aminoacetamide derivatives | FISONS CORPORATION (US) | 1988-08-31 | — | — | EP | disclosed |
| EP-0278089-A2 | 2-Azacyclocarboxamide derivatives | FISONS CORPORATION (a Massachusetts corporation) (US) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2D, GRIN2A, GRIN2C | TAAR1 123/4885SLC6A2 141/4885SIGMAR1 232/4885 |
| US-20150359759-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | MECP2, GRIN2A, GRIN2C | TAAR1 726/4885SLC6A2 136/4885SIGMAR1 2234/4885 |
| US-11213494-B2 | Compositions and methods for the treatment of pervasive development disorders | GRIN2A, GRIN2C, GRIN2D | TAAR1 193/4885SLC6A2 126/4885SIGMAR1 1401/4885 |
| US-20180008559-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2A, GRIN2C, GRIN2D | TAAR1 193/4885SLC6A2 126/4885SIGMAR1 1401/4885 |
| US-10555916-B2 | NMDAR antagonist for the treatment of pervasive development disorders | MECP2, GRIN2A, GRIN2B | TAAR1 669/4885SLC6A2 197/4885SIGMAR1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.